Assess whether product recall exposure is priced or excluded (6ff0a5)

SITUATION D&O specialist in a cedent submitting a property treaty with thin bordereaux has one working extract — umbrella underlying-limit adequacy memo — after a product that just got an FDA warning letter. If umbrella underlying-limit adequacy memo cannot support product recall exposure is, the only defensible Insurance Underwriting output is hold.

DECISION D&O specialist in a cedent submitting a property treaty with thin bordereaux must choose Product recall exposure is priced / Excluded using umbrella underlying-limit adequacy memo after a product that just got an FDA warning letter.

HYPOTHESES TO TEST 1. Umbrella underlying-limit adequacy memo reads as Product recall exposure is priced once a product that just got an FDA warning letter is lined up to the same Insurance Underwriting population. 2. Umbrella underlying-limit adequacy memo is closer to Excluded after a product that just got an FDA warning letter; Product recall exposure is priced would over-claim this Specialty Liability extract. 3. A dual reading is still live in umbrella underlying-limit adequacy memo for D&O specialist in a cedent submitting a property treaty with thin bordereaux. 4. Umbrella underlying-limit adequacy memo is missing the fact D&O specialist needs after a product that just got an FDA warning letter; stop this Insurance Underwriting close.

ANALYSIS REQUIRED 1. Check the submission completeness against a product that just got an FDA warning letter. 2. Say whether a cedent submitting a property treaty with thin bordereaux can bind, restrict, or decline from the file as it stands. 3. Test exposure, limits, and endorsement language in umbrella underlying-limit adequacy memo after a product that just got an FDA warning letter. 4. For this Insurance Underwriting Specialty Liability file, read umbrella underlying-limit adequacy memo against a product that just got an FDA warning letter and write the one fact that would move product recall exposure is for D&O specialist.

RECOMMENDATION Choose Product recall exposure is priced / Excluded on this Insurance Underwriting / Specialty Liability packet (umbrella underlying-limit adequacy memo after a product that just got an FDA warning letter). Lead with the Insurance Underwriting option umbrella underlying-limit adequacy memo can support after a product that just got an FDA warning letter, then the two facts that force it, then the Monday action for D&O specialist in a cedent submitting a property treaty with thin bordereaux.

COMMAND RETURNS - Bottom-line Insurance Underwriting option on product recall exposure is, then the evidence in umbrella underlying-limit adequacy memo, then the action for D&O specialist - Hypothesis scorecard against umbrella underlying-limit adequacy memo: supported / rejected / untestable - Missing page in umbrella underlying-limit adequacy memo after a product that just got an FDA warning letter, if any - Regulatory or exam hook Specialty Liability would cite